search
Back to results

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

Primary Purpose

Non-Small Cell Lung Cancer

Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Tislelizumab
Paclitaxel
Nab-paclitaxel
Carboplatin
Sponsored by
BeiGene
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Small Cell Lung Cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  1. Age 18-75 years old, male or female, signed informed consent form (ICF).
  2. Advanced NSCLC diagnosed by pathological or clinical physicians
  3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1
  4. Participants must have ≥ 1 measurable lesion as defined per RECIST v1.1
  5. Must be treatment-naive for locally advanced or metastatic squamous NSCLC.
  6. Life expectancy ≥ 12 weeks
  7. Participants must have adequate organ function
  8. Male/Female is willing to use a highly effective method of birth control

Key Exclusion Criteria:

  1. Diagnosed with NSCLC but with epidermal growth factor receptors (EGFR)-sensitizing mutation or ALK gene translocation
  2. Received any approved systemic anticancer therapy
  3. Received prior treatment with EGFR inhibitors or ALK inhibitors
  4. Received prior therapies targeting PD-1 or PD-L1
  5. With history of interstitial lung disease
  6. Clinically significant pericardial effusion
  7. Sever infections, Active leptomeningeal disease or uncontrolled, untreated brain metastasis
  8. Any major surgical procedure before randomization
  9. HIV infection
  10. Participant with untreated hepatitis B virus (HBV)/hepatitis C virus (HCV)
  11. Active autoimmune diseases or history of autoimmune diseases
  12. History of allergic reactions to chemotherapy

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Sites / Locations

  • Anhui Provincial Hospital
  • The First Affiliated Hospital of Anhui Medical University
  • Cancer Hospital Chinese Academy of Medical Sciences
  • Beijing Cancer Hospital
  • Beijing Hospital
  • Peking Union Medical College Hospital
  • Chinese PLA General Hospital
  • Beijing Chest Hospital,Capital Medical University
  • The Second Affiliated Hospital of Chongqing Medical University
  • The First Hospital Affiliated to AMU (Southwest Hospital)
  • Daping Hospital of The 3rd Military University
  • Chongqing Sanxia Central Hospital
  • Fujian Tumor Hospital
  • The First Affiliated Hospital of Xiamen University
  • Nanfang Hospital of Southern Medical University
  • Cancer Center of Guangzhou Medical University
  • Cancer Hospital of Shantou University Medical College
  • The People's Hospital of Guangxi Zhuang Autonomous Region
  • Affiliated Hospital of Zunyi Medical College
  • Harbin Medical University Cancer Hospital
  • Henan Cancer Hospital
  • The First Affiliated Hospital, Zhengzhou University
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
  • Hubei Cancer Hospital
  • 2nd Hospital of Central South University
  • Hunan Cancer Hospital
  • Nanjing General Hospital
  • Jiangsu Province Hospital
  • The First Affiliated Hospital of Soochow University
  • Xuzhou Central Hospital
  • The First Hospital of Jilin University
  • Liaoning Cancer Hospital & Institute
  • Jinan Central Hospital
  • The 96th Hospital of the Joint Service Support Force of the People's Liberation Army of China
  • Shandong Cancer Hospital
  • Qilu Hospital of Shandong University
  • Weifang People's Hospital
  • Shanghai Chest Hospital
  • The First Affiliated Hospital of Xi'an Jiaotong University
  • West China Hospital, Sichuan University
  • Tianjin Medical University General Hospital
  • Tianjin Medical University Cancer Institute & Hospital
  • Hangzhou First People's Hospital
  • The First Affiliated Hospital, Zhejiang University
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
  • Zhejiang Cancer Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Tislelizumab + Paclitaxel + Carboplatin

Tislelizumab + Nab-paclitaxel + Carboplatin

Paclitaxel + Carboplatin

Arm Description

Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)

Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)

Paclitaxel 175 mg/m^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)

Outcomes

Primary Outcome Measures

Progression-free Survival (PFS) by Independent Review Committee (IRC) Assessment
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Secondary Outcome Measures

Overall Survival (OS)
OS is defined as the time from randomization until the date of death due to any cause
Objective Response Rate (ORR) by IRC and Investigator Assessment
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC and investigator using RECIST v1.1.
Duration of Response (DOR) by IRC and Investigator Assessment
DOR is defined as the time from the first occurrence of a documented objective response to the time of relapse or death from any cause, whichever comes first, as assessed by the IRC and the investigator using RECIST v1.1 in all randomized participants with documented objective responses.
Progression-free Survival (PFS) by Investigator Assessment
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1
PFS Based on Programmed Death Ligand 1 (PD-L1) Expression
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1 based on PD-L1 expression
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)
Mean change from baseline in EORTC QLQ-CL13 scores for dyspnea, cough, and chest pain. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0

Full Information

First Posted
July 3, 2018
Last Updated
October 13, 2023
Sponsor
BeiGene
search

1. Study Identification

Unique Protocol Identification Number
NCT03594747
Brief Title
A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer
Official Title
A Phase 3, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non-small Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Completed
Study Start Date
July 30, 2018 (Actual)
Primary Completion Date
September 30, 2020 (Actual)
Study Completion Date
April 28, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BeiGene

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Small Cell Lung Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
360 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tislelizumab + Paclitaxel + Carboplatin
Arm Type
Experimental
Arm Description
Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
Arm Title
Tislelizumab + Nab-paclitaxel + Carboplatin
Arm Type
Experimental
Arm Description
Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
Arm Title
Paclitaxel + Carboplatin
Arm Type
Active Comparator
Arm Description
Paclitaxel 175 mg/m^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)
Intervention Type
Drug
Intervention Name(s)
Tislelizumab
Other Intervention Name(s)
BGB-A317
Intervention Description
Administered intravenously as described
Intervention Type
Drug
Intervention Name(s)
Paclitaxel
Intervention Description
Administered intravenously as described
Intervention Type
Drug
Intervention Name(s)
Nab-paclitaxel
Intervention Description
Administered intravenously as described
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Administered intravenously as described
Primary Outcome Measure Information:
Title
Progression-free Survival (PFS) by Independent Review Committee (IRC) Assessment
Description
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Time Frame
Up to approximately 2 years and 2 months; data presented as of primary analysis data cut off date of 30SEP2020
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Description
OS is defined as the time from randomization until the date of death due to any cause
Time Frame
Up to approximately 2 years and 2 months
Title
Objective Response Rate (ORR) by IRC and Investigator Assessment
Description
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC and investigator using RECIST v1.1.
Time Frame
Up to approximately 2 years and 2 months
Title
Duration of Response (DOR) by IRC and Investigator Assessment
Description
DOR is defined as the time from the first occurrence of a documented objective response to the time of relapse or death from any cause, whichever comes first, as assessed by the IRC and the investigator using RECIST v1.1 in all randomized participants with documented objective responses.
Time Frame
Up to approximately 2 years and 2 months
Title
Progression-free Survival (PFS) by Investigator Assessment
Description
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1
Time Frame
Up to approximately 2 years and 2 months
Title
PFS Based on Programmed Death Ligand 1 (PD-L1) Expression
Description
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1 based on PD-L1 expression
Time Frame
Up to approximately 2 years and 2 months
Title
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)
Description
Mean change from baseline in EORTC QLQ-CL13 scores for dyspnea, cough, and chest pain. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.
Time Frame
Baseline to Cycle 5; up to approximately 2 years and 2 months; each cycle is 21 days
Title
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Description
Mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time Frame
Baseline to Cycle 5; up to approximately 2 years and 2 months; each cycle is 21 days
Title
Number of Participants With Adverse Events
Description
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Time Frame
Up to approximately 4 years and 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Age 18-75 years old, male or female, and signed informed consent form (ICF) Advanced NSCLC diagnosed by pathological or clinical physicians Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1 Participants must have ≥ 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Must be treatment-naive for locally advanced or metastatic squamous NSCLC Life expectancy ≥ 12 weeks Participants must have adequate organ function Male/Female is willing to use a highly effective method of birth control Key Exclusion Criteria: Diagnosed with NSCLC but with epidermal growth factor receptors (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation Received any approved systemic anticancer therapy Received prior treatment with EGFR inhibitors or ALK inhibitors Received prior therapies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) With history of interstitial lung disease Clinically significant pericardial effusion Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis Any major surgical procedure before randomization Human immunodeficiency virus infection Untreated hepatitis B virus (HBV)/hepatitis C virus (HCV) Active autoimmune diseases or history of autoimmune diseases History of allergic reactions to chemotherapy NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Study Director
Organizational Affiliation
BeiGene
Official's Role
Study Director
Facility Information:
Facility Name
Anhui Provincial Hospital
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230001
Country
China
Facility Name
The First Affiliated Hospital of Anhui Medical University
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230022
Country
China
Facility Name
Cancer Hospital Chinese Academy of Medical Sciences
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100021
Country
China
Facility Name
Beijing Cancer Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Facility Name
Beijing Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
Peking Union Medical College Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100730
Country
China
Facility Name
Chinese PLA General Hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100853
Country
China
Facility Name
Beijing Chest Hospital,Capital Medical University
City
Beijing
State/Province
Beijing
ZIP/Postal Code
101149
Country
China
Facility Name
The Second Affiliated Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400010
Country
China
Facility Name
The First Hospital Affiliated to AMU (Southwest Hospital)
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400038
Country
China
Facility Name
Daping Hospital of The 3rd Military University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400042
Country
China
Facility Name
Chongqing Sanxia Central Hospital
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
404000
Country
China
Facility Name
Fujian Tumor Hospital
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350014
Country
China
Facility Name
The First Affiliated Hospital of Xiamen University
City
Xiamen
State/Province
Fujian
ZIP/Postal Code
361003
Country
China
Facility Name
Nanfang Hospital of Southern Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510515
Country
China
Facility Name
Cancer Center of Guangzhou Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
528400
Country
China
Facility Name
Cancer Hospital of Shantou University Medical College
City
Shantou
State/Province
Guangdong
ZIP/Postal Code
515031
Country
China
Facility Name
The People's Hospital of Guangxi Zhuang Autonomous Region
City
Nanning
State/Province
Guangxi
ZIP/Postal Code
530021
Country
China
Facility Name
Affiliated Hospital of Zunyi Medical College
City
Zunyi
State/Province
Guizhou
ZIP/Postal Code
563099
Country
China
Facility Name
Harbin Medical University Cancer Hospital
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150081
Country
China
Facility Name
Henan Cancer Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450008
Country
China
Facility Name
The First Affiliated Hospital, Zhengzhou University
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450052
Country
China
Facility Name
Union Hospital Tongji Medical College Huazhong University of Science and Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430022
Country
China
Facility Name
Hubei Cancer Hospital
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430079
Country
China
Facility Name
2nd Hospital of Central South University
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410011
Country
China
Facility Name
Hunan Cancer Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Facility Name
Nanjing General Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210002
Country
China
Facility Name
Jiangsu Province Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215004
Country
China
Facility Name
Xuzhou Central Hospital
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221009
Country
China
Facility Name
The First Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Facility Name
Liaoning Cancer Hospital & Institute
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110042
Country
China
Facility Name
Jinan Central Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250013
Country
China
Facility Name
The 96th Hospital of the Joint Service Support Force of the People's Liberation Army of China
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250031
Country
China
Facility Name
Shandong Cancer Hospital
City
Jinan
State/Province
Shandong
ZIP/Postal Code
250117
Country
China
Facility Name
Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
Country
China
Facility Name
Weifang People's Hospital
City
Weifang
State/Province
Shandong
ZIP/Postal Code
261041
Country
China
Facility Name
Shanghai Chest Hospital
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200030
Country
China
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710061
Country
China
Facility Name
West China Hospital, Sichuan University
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610041
Country
China
Facility Name
Tianjin Medical University General Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300052
Country
China
Facility Name
Tianjin Medical University Cancer Institute & Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300060
Country
China
Facility Name
Hangzhou First People's Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310002
Country
China
Facility Name
The First Affiliated Hospital, Zhejiang University
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310003
Country
China
Facility Name
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310016
Country
China
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310022
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
33792623
Citation
Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J, Leaw SJ, Zhang J, Lin X, Liang L, Yang N. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366.
Results Reference
background
Citation
Wang, J, S. Lu, et al. Randomized Phase III Study of Tislelizumab plus Chemotherapy versus Chemotherapy Alone as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer (Sq-NSCLC): RATIONALE-307 Updated Analysis. IOTECH Abstract, Vol. 16 Supplement 1, Dec. 2022. doi.org/10.1016/j.iotech.2022.100244.
Results Reference
background

Learn more about this trial

A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer

We'll reach out to this number within 24 hrs